TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02961335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Confocal microendoscopy
Description: Confocal microendoscopy will be performed during this initial bronchoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy sampling
Description: Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
Study: NCT02609360

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Priming of ECMO circuit with 0.9% NaCl
Description: 0.9% NaCl as priming crystalloid solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Priming of ECMO circuit with Ringer Lactate
Description: Ringer Lactate as priming crystalloid solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Priming of ECMO circuit with Balanced Solution
Description: Balanced Solution as priming crystalloid solution
Study: NCT03333031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-196
Description: HS-196 will be administered intravenously as a single dose
Study: NCT00110773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)
Description: S-Caine Peel, composed of a 1:1 (w:w) eutectic mixture of 7% lidocaine and 7% tetracaine, applied topically. S-Caine Peel applied at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Peel
Description: Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
Study: NCT01789450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Section of Periareolar Dermis in Breast Reduction.
Study: NCT02229552

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized Assessments
Description: Children were asked to attend appointments without consuming study foods 24 hours previously, as habituation measurements are sensitive to recent consumption. Children were provided access to snack prior to completing questionnaires or cognitive assessments. Habituation to food, questionnaires and cognitive assessments were re-measured at 1-year and 2-year follow up.
Study: NCT04388995

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: volume expansion
Description: volume expansion with 6% hydroxyethyl starch (7 mL/kg) at a rate of 0.4 mL/kg/min
Study: NCT01692301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 200 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: 20 mg and 40 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 matching placebo
Description: LCZ696 Matching Placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCZ696 matching placebo
Description: LCZ696 Matching Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan matching placebo
Description: Olmesartan matching placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Description: amlodipine 2.5 mg or 5 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine 2.5 mg or 5 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Description: hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide
Description: hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
Study: NCT00467454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily
Study: NCT04580381

Intervention type: DRUG
Intervention: Natalizumab Injection [Tysabri]
Description: Natalizumab infusion interval according to local practice defining the patient's group

Intervention type: DRUG
Intervention: Natalizumab Injection [Tysabri]
Description: Natalizumab infusion interval according to local practice defining the patient's group
Study: NCT03604965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+CCRT
Description: Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPF+CCRT
Description: Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
Study: NCT00566930

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Description: Monthly cervical spinal manipulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulation + exercises
Description: Monthly cervical spine manipulation and daily home exercises
Study: NCT04360902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anemia Controller
Description: Model Predictive Controller software (called Anemia Controller) that utilizes our physiology-based erythropoiesis model to provide ESA dosing recommendations in order to guide a patient's Hgb level towards a predefined target value.
Study: NCT04515732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Oral Tablet
Description: As in description
Study: NCT02905565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NBP Softgel Capsules
Description: Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
Study: NCT02767648

Intervention type: OTHER
Intervention: proteomic urine analysis
Description: proteomic urine analysis
Study: NCT02762474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel group
Description: Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT
Study: NCT03664414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxifylline
Description: Pentoxifylline or placebo will be prescribed three times a day with meals. All the participants will continue with the usual treatment. Time frame: two years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pentoxifylline
Description: Pentoxifylline or placebo will be prescribed three times a day with meals. All the participants will continue with the usual treatment. Time frame: two years
Study: NCT03987854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and lifestyle program
Description: Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep. They will also be taught taught about positive affect skills (such as gratitude, positive reappraisal, and personal strengths) and mindfulness (general mindfulness and mindful eating).
Study: NCT02138032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gains Framed Message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Framed Message
Study: NCT04577443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: To investigate the role of adenosine on cerebral hemodynamic and headache in healthy volunteers and migraine patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
Study: NCT04659460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Description: RIC interventions will be applied to the upper extremity calibrated to induce four, ten-minute cycles of five-minutes-ischemia and five-minutes-perfusion for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Remote Ischemic Conditioning
Description: RIC interventions will be applied to the upper extremity calibrated to induce four, ten-minute cycles of five-minutes-ischemia and five-minutes-perfusion for a total of 20 cumulative minutes of limb ischemia, at a pressure of 250 mmHg.
Study: NCT02958488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Study: NCT04027998

Intervention type: DIAGNOSTIC_TEST
Intervention: strain and applied pressure measurement
Description: Measurement of median nerve strain and applied pressure at proximal carpal tunnel level

Intervention type: DIAGNOSTIC_TEST
Intervention: strain and applied pressure measurement
Description: Measurement of median nerve strain and applied pressure at proximal carpal tunnel level
Study: NCT03003208

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary rehabilitation
Description: An exercise and education program
Study: NCT00847366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab was given 6mg/kg i.v. daily or 2 mg/kg i.v. on day 1, 8 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Endocrine therapy with tamoxifen will be evaluated in combination with perifosine to determine if the combination overcomes resistance to endocrine therapy .
Study: NCT04196868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Description: 1500 mg once a day, per os, during six months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: per os, during six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate treatment
Description: per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate treatment
Description: per os
Study: NCT00367042

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Scalpel for tissue scoring
Description: During Mohs surgery we will compare the outcomes of scarring, to determine whether a mark (with a pen) or a score with a scalpel will receive the best scar.

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Surgical marker for tissue marking
Description: You will be asked to participate, examined, discuss participation have procedure and come in for follow up for photos and check up.
Study: NCT02723123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recording of cardio-respiratory signals
Description: Biological signals: ECG, RIP, SpO2 and Pulse rate will be recorded during the interventions and analyzed offline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recording of cardio-respiratory signals
Description: Biological signals: ECG, RIP, SpO2 and Pulse rate will be recorded during the interventions and analyzed offline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recording of cardio-respiratory signals
Description: Biological signals: ECG, RIP, SpO2 and Pulse rate will be recorded during the interventions and analyzed offline.
Study: NCT02072031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib maleate
Description: Sunitinib 50 mg p.o. qd
Study: NCT02936141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Description: Includes a group (up to 10 participants) weekly session with a duration of 90 minutes where it is stimulated communication, adaptative behaviour and social living
Study: NCT03937583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose 18F
Description: The performance of the 18 FDG PET-CT will require fasting of at least 6 hours, and the glycemia will have to be lower than 126 mg / dL before the injection of 3-5 MBq / kg of 18FDG. Intravenous injection will follow a period of approximately 60 minutes in a quiet room.~Computed tomography (CT) will be performed from the middle of the forehead to the feet with normal and shallow breathing using a low dose adjustment Iodinated contrast will not be administered intravenously.
Study: NCT00144482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin
Description: 36000IU（0.5mL）s.c./week for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: recombinant human erythropoietin placebo
Description: 0 IU(0.5mL)s.c./week for 8 weeks
Study: NCT00745563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fertiligent
Description: Fertility treatment by using the EVIE - Slow Release Insemination method
Study: NCT00776607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoMix 30
Description: Insulin arm: Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal. Dose will be adjusted in increments of 2-6U depending on fasting glucose level When total dose equals 16 U patient will be started on 4 units with breakfast and continue with 16 units with evening meal. Breakfast and/or evening meal dose will be adjusted where necessary at increments of 2-6 U depending on fasting and/or pre-evening meal glucose level. Patient needs to keep a daily diary of insulin doses taken.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablet treatment
Description: Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
Study: NCT04235556

Intervention type: BEHAVIORAL
Intervention: Care pathway unit
Description: Patients from the prospective cohort will have their health care scheduled by the care pathway unit.
Study: NCT05204264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: This intervention uses techniques based on mindfulness, metaphors and exposition exercises both in imagination and in real contexts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Emotional Regulation (MER)
Description: This intervention includes both formal practices of body scan meditation, standing / sitting Hatha yoga, meditations focused on the breath or other objects of attention, exercises of benevolence or kindness with affection (loving-kindness); as well as informal mindfulness practices in activities of daily living.
Study: NCT00120458

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black cohosh
Description: 32 to 128 mg (black cohosh)~1 to 4 capsules daily (placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Black cohosh
Description: 32 to 128 mg (black cohosh)~1 to 4 capsules daily (placebo)
Study: NCT02627820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isis 420915/GSK 299872
Description: Open label study in comparison to historic control.
Study: NCT01981642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recording of LVAD data during routine visits and daily life.
Description: Noninvasive diagnostic intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recording of daily activity using wristwatch accelerometers.
Description: Noninvasive diagnostic intervention.
Study: NCT02092571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal ring,
Description: Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal ring,
Description: Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
Study: NCT04406909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to training facility
Description: Access to training facility under national regulations for COVID control
Study: NCT01738334

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator (meditation) with healthy subjects
Description: The control group with healthy subjects that was participate in meditation (active control group)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: In the eight weeks following the first session of cognitive tests, the participants made a practice of weekly meditation group lasting 2 hours. Practices with each group (patients and active controls) occurred on different days. With regard to meditation practices were performed in a sitting posture with emphasis on daily life. Each weekly session involved meditation practices with trained professional, practical proposals for home exercise and a discussion group. Meditation compact discs (CDs)were given to participants for practices at home, which proposed activities for 5 minutes to 1 week and 2 weeks for 10 minutes 3-5, and finally 15 minutes for 6-8 weeks. After 8 weeks of treatment the second session of tests was held that involved the same tasks in session 1.
Study: NCT03712397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: combination therapy of nal-IRI , leucovorin and 5-FU in sequence at day 1, every 14 days counted as one cycle
Study: NCT00847483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% ophthalmic solution
Description: One drop in the evening in the affected eye(s) at 8:00pm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 004% sterile ophthalmic solution
Description: One drop in the evening in the affected eye(s) at 8:00pm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost .03% sterile ophthalmic solution
Description: One drop in the evening in the affected eye(s) at 8:00pm
Study: NCT02990442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: repetitive transcranial magnetic stimulation, 1Hz protocol to right dorsolateral pre frontal cortex (R_DLPFC)
Study: NCT01076582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP (YAZ, BAY86-5300)
Description: 4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)
Description: 4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days
Study: NCT06317480

Intervention type: PROCEDURE
Intervention: bone resection
Description: patients underwent soft tissue sarcoma excision together with bone resection following either biological or endoprosthesis reconstruction

Intervention type: PROCEDURE
Intervention: subperiosteal excision
Description: patients underwent sub-periosteal tumor excision combining bone and soft tissue ablation without bone excision
Study: NCT02611986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the McGrath MAC
Description: in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Macintosh Laryngoscope
Description: in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
Study: NCT00368771

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBS Stress Management
Description: If randomly assigned to this intervention, the session with the therapist will consist of training about IBS symptoms and their relationship to stress, as well as skills training in relaxation and ways of identifying and challenging mistaken thoughts about life events. The goal of this treatment is to lessen mental and physical stressful reactions to daily events, and therefore lessen IBS symptoms as a reaction to stress. The patient will be encouraged to apply relaxation skills to stressful situations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBS Symptom Management
Description: If assigned to this group, the therapist will discuss feelings, over-attention to IBS symptoms, and your fear of IBS symptoms. Patients will learn how to identify thoughts that may increase your IBS symptoms and will practice how to change these thoughts to ones that make them feel more comfortable. The sessions will focus on reactions to daily life that in turn result in IBS Symptoms.
Study: NCT01926210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mild stimulation protocol
Description: letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.